Brain Tumours

Brain tumours are one of the strongest translational areas for mebendazole because the literature includes meaningful preclinical CNS work and clinical repurposing interest.

Overview

The strongest evidence here is in medulloblastoma and broader CNS tumour models, where mebendazole combines anti-angiogenic, anti-mitotic, and survival-prolonging effects.

Key findings

• Mebendazole was effective across diverse medulloblastoma models

• It selectively inhibited VEGFR2-driven angiogenesis in brain tumour models

• Survival extension was reported with minimal effect on normal brain vasculature

• Broader CNS tumour repurposing reviews support ongoing clinical interest

Clinical positioning

This is one of the most important pages in the topic because CNS-tumour repurposing is one of the clearest current niches for mebendazole.

References

Effective treatment of diverse medulloblastoma models with mebendazole
https://pmc.ncbi.nlm.nih.gov/articles/PMC4483072/

Repurposing the anthelmintic drug mebendazole in CNS tumour research
https://academic.oup.com/noa/article/7/1/vdaf066/8097633